2016-08-15
Wedbush has started coverage of Audentes Therapeutics Inc (NASDAQ: BOLD) with an Outperform rating and $20 price target, citing the stock as "a compelling opportunity."
Latest Ratings for BOLD
Date
Firm
Action
From
To
Aug 2016
Wedbush
Initiates Coverage on
Outperform
Aug 2016
Cowen & Company
Initiates Coverage on
Outperform
Aug 2016
PiperJaffray
Initiates Coverage on
Overweight
View More Analyst Ratings for BOLD
View the Latest Analyst Ratings